Y Intercept (Hong Kong) LTD Savara Inc Transaction History

Y Intercept (Hong Kong) LTD

  • $1.58 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024
BUY
$4.19 - $5.59 $49,454 - $65,978
11,803 New
11,803 $58,000
Q1 2023

May 09, 2023
BUY
$1.6 - $2.82 $64,102 - $112,980
40,064 New
40,064 $78,000
Q3 2021

Nov 15, 2021
SELL
$1.18 - $1.64 $13,026 - $18,103
-11,039 Closed
0 $0
Q2 2021

Aug 26, 2021
BUY
$1.51 - $2.29 $16,668 - $25,279
11,039 New
11,039 $19,000

Others Institutions Holding SVRA

# of Institutions
128
Shares Held
158M
Call Options Held
67.6K
Put Options Held
29.4K
View Full List

About Savara Inc

SVRA Quotes by TradingView
  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $365M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Y Intercept (Hong Kong) LTD Portfolio

Follow Y Intercept (Hong Kong) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email